Free press releases distribution network?

More news: Health/Surgery
Agency / Source: Cellonis Biotechnologies Co., Ltd

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Cellonis Biotechnologies Co., Ltd Introduces Diabetes Stem Cell Therapy – Insulin Independence and the Reversal of Complications - Cellonis, a Beijing and HK-based biotech company, with its new personalized diabetes treatment has demonstrated in the best case that it could reconstruct a patient's natural insulin production and even reverse later complications in a clinical study
Cellonis Biotechnologies Co., Ltd Introduces Diabetes Stem Cell Therapy – Insulin Independence and the Reversal of Complications

 

PRZOOM - /newswire/ - Beijing, China, 2010/06/24 - Cellonis, a Beijing and HK-based biotech company, with its new personalized diabetes treatment has demonstrated in the best case that it could reconstruct a patient's natural insulin production and even reverse later complications in a clinical study.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The clinical study, jointly conducted by scientists and doctors of the Cellonis clinical research team, aims to help patients be free from insulin and oral drugs, by reconstructing their natural insulin production damaged by either autoimmune disorder (T1DM) or hyperglycemia, and also improve insulin sensitivity (T2DM). Using injections of autologous stem cells from the patient's bone marrow, the research team believes that this therapy could help patients return to a life without annoying everyday injections and drugs.

"Most of the patients in our clinical study are now taking less synthetic insulin or oral drugs for BG control," says Dr. Chase Dai, Chief Medical Officer at Cellonis. “We appear to have restored the biological insulin producing function of the body. We are excited to see that some patients have been treatment-free for five months now, and we believe the effect of the stem cell therapy can last much longer. We were also encouraged by some other happy surprises during the clinical study.

"For example, this therapy appears to reverse chronic kidney failure. It was a surprise for all of my team to observe that the kidney function of a 75-year-old patient improved remarkably."

This patient had suffered from diabetes for years, gradually developing diabetic foot and nephropathy. He can now walk freely after having been confined to bed or a wheelchair for six months, and his quality of life has improved significantly. Moreover, he only needs kidney dialysis one time a week instead of three times. In a follow-up visit he excitedly told us that he was hopeful that in the near future he could be completely rid of diabetes.

A 19-year-old boy, diagnosed as T1DM five years ago, received his first Diabetes Stem Cell Cocktail in December 2009. He said: “I am physically recovered and mentally improved markedly. My blood sugar is very stable, around 5 mmol/L and I even don’t even need insulin injections anymore. This insulin-independent condition is a dream that I always have had and now it comes true.

Diabetes, an increasingly spreading disease, can lead to life-threatening diseases such as blindness, amputation, strokes, or kidney failure in its natural course. Current treatments, including insulin, cannot change this situation.

"We believe that our stem cell therapy will bring promising hope for patients suffering from diabetes and its complications," comments Cindy Hao, CEO of Cellonis. "Personalized diabetes therapies for patients of various conditions will be developed by Cellonis in the near future. We believe what we have restored for patients will not only be their natural insulin production, but also a normal life filled with the activities non-diabetes sufferers can enjoy daily."

Cellonis Biotechnologies (cellonis.com) focuses on R&D and the clinical application of novel personalized stem cell therapies and immunotherapies for patients with diseases including cancer, diabetes and central nervous system disorders.

Contact: Urs J. Lienert, COO-International, Cellonis Biotechnologies Co., Ltd, +86-150-1054-7487, urs.lienert[.]cellonis.com.

Cellonis Biotechnology is a Beijing and Hong Kong-based biotechnology company focused on Research & Development, Clinical Trials and Application of novel cell and stem cell therapies and immunotherapies for providing in their partner hospitals effective, personalized therapies for patients with diseases such as different cancers, diabetes and CNS.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Cellonis Biotechnologies Co., Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Health/Surgery articles,
CATCH Visitors via Your Competitors Announcements!


Cellonis Biotechnologies Co., Ltd Introduces Diabetes Stem Cell Therapy – Insulin Independence and the Reversal of Complications

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Emily Yang - Cellonis.com 
+86 10-13466336208 zhuoniyang[.]cellonis.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Cellonis Biotechnologies Co., Ltd securities in any jurisdiction including any other companies listed or named in this release.

Health/Surgery via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Cellonis Biotechnologies Co., Ltd / Company Profile


Read Health/Surgery Most Recent Related Press Releases:

Lutein & Zeaxanthin Supplementation Could Save EU Billions in Healthcare Costs Associated with Age-related Macular Degeneration Says Frost & Sullivan
Frost & Sullivan Commends Columbia Pacific’s Clear Vision in the Healthcare Delivery Space and Senior Living Services
Global Acute Myeloid Leukemia Treatment Market to Reach US$ 1.17 Billion by 2021 According to iHealthcareAnalyst, Inc.
Frost & Sullivan Recognizes Prognos for its Commitment to Develop Novel Artificial Intelligence Based Platfor
DSM Partners with the Musculoskeletal Transplant Foundation for Distribution of Regenerative Materials and Products
USACS Announces New Integrated Acute Care Partnership with Sharon Regional Health System
Frost & Sullivan Highlights STANLEY Healthcare's Design Innovation and Leadership in Addressing the Changing Needs of the Senior Living Industry
USACS Additional Integrated Acute Care Partnership with MetroSouth Medical Center
Big Data Analytics to Disrupt U.S. Next-generation Sequencing Informatics Market with Double-digit Growth
Bionic Prosthetics Manufacturers Drive R&D Initiatives across Emerging Markets to Impel its Adoption

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  SKS Media | SKS Associates Ltd

Visit  La Bella Bakery Artisan Bakery Arizona

Visit  NAKIVO, Inc.







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today